Olezarsen effectively lowered triglyceride levels in the blood of people at high cardiac risk
US and Canadian scientists have found in a phase II clinical trial of the experimental drug olesarsen that it effectively reduces levels of triglycerides, apolipoprotein B and non-high-density lipoprotein cholesterol in patients at high cardiovascular risk
19.06.2024